N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide
| Title | Journal |
|---|---|
| Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. | Expert opinion on pharmacotherapy 20150501 |
| Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. | Cellular signalling 20140901 |
| A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. | Dermatology online journal 20140516 |
| Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4. | Journal of the American Academy of Dermatology 20130601 |
| Phosphodiesterase 4-targeted treatments for autoimmune diseases. | BMC medicine 20130101 |
| Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. | Lancet (London, England) 20120825 |
| Apremilast: a step forward in the treatment of psoriasis? | Lancet (London, England) 20120825 |
| Novel systemic drugs under investigation for the treatment of psoriasis. | Journal of the American Academy of Dermatology 20120701 |
| Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. | Biochemical pharmacology 20120615 |
| A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. | Journal of drugs in dermatology : JDD 20120301 |
| [New therapeutic targets in psoriatic arthritis]. | Reumatologia clinica 20120301 |
| Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. | Archives of dermatology 20120201 |
| Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. | Xenobiotica; the fate of foreign compounds in biological systems 20111201 |
| Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. | British journal of pharmacology 20100201 |
| Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. | Arthritis research & therapy 20100101 |
| Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. | Journal of medicinal chemistry 20090326 |
| An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. | Current medical research and opinion 20080501 |
| 10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA. | Expert opinion on investigational drugs 20060601 |
| CC-1088 Celgene. | Current opinion in investigational drugs (London, England : 2000) 20050501 |
| CC-10004 . | Current opinion in investigational drugs (London, England : 2000) 20050501 |
| The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures. | British journal of haematology 20040201 |